OCUL
Income statement / Annual
Last year (2025), Ocular Therapeutix Inc's total revenue was $51.82 M,
a decrease of 18.67% from the previous year.
In 2025, Ocular Therapeutix Inc's net income was -$265.94 M.
See Ocular Therapeutix Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$51.82 M |
$63.72 M |
$58.44 M |
$51.49 M |
$43.52 M |
$17.40 M |
$4.23 M |
$1.99 M |
$1.92 M |
$1.89 M |
| Cost of Revenue |
$6.57 M
|
$5.63 M
|
$5.28 M
|
$4.54 M
|
$4.41 M
|
$2.08 M
|
$2.33 M
|
$465.00 K
|
$457.00 K
|
$443.00 K
|
| Gross Profit |
$45.25 M
|
$58.10 M
|
$53.16 M
|
$46.95 M
|
$39.12 M
|
$15.32 M
|
$1.90 M
|
$1.53 M
|
$1.47 M
|
$1.44 M
|
| Gross Profit Ratio |
0.87
|
0.91
|
0.91
|
0.91
|
0.9
|
0.88
|
0.45
|
0.77
|
0.76
|
0.77
|
| Research and Development Expenses |
$197.10 M
|
$127.64 M
|
$61.06 M
|
$53.46 M
|
$50.08 M
|
$28.69 M
|
$41.09 M
|
$36.92 M
|
$30.88 M
|
$27.07 M
|
| General & Administrative Expenses |
$64.38 M
|
$60.65 M
|
$33.94 M
|
$67.98 M
|
$31.88 M
|
$22.86 M
|
$22.12 M
|
$18.79 M
|
$15.51 M
|
$11.00 M
|
| Selling & Marketing Expenses |
$53.92 M
|
$41.59 M
|
$40.55 M
|
$4.17 M
|
$35.19 M
|
$26.61 M
|
$24.49 M
|
$4.94 M
|
$17.00 M
|
$6.70 M
|
| Selling, General & Administrative Expenses |
$118.30 M
|
$102.24 M
|
$74.49 M
|
$72.15 M
|
$67.07 M
|
$49.47 M
|
$46.61 M
|
$23.73 M
|
$32.51 M
|
$17.71 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.00 K
|
-$1.00 K
|
| Operating Expenses |
$315.39 M
|
$229.88 M
|
$135.54 M
|
$125.61 M
|
$117.15 M
|
$78.17 M
|
$87.70 M
|
$60.64 M
|
$63.39 M
|
$44.77 M
|
| Cost And Expenses |
$321.97 M
|
$235.50 M
|
$140.83 M
|
$130.15 M
|
$121.56 M
|
$80.25 M
|
$90.03 M
|
$61.11 M
|
$63.85 M
|
$45.21 M
|
| Interest Income |
$18.36 M
|
$20.28 M
|
$3.98 M
|
$798.00 K
|
$33.00 K
|
$168.00 K
|
$1.23 M
|
$879.00 K
|
$424.00 K
|
$304.00 K
|
| Interest Expense |
$11.84 M
|
$13.58 M
|
$11.34 M
|
$7.02 M
|
$6.67 M
|
$6.77 M
|
$6.10 M
|
$1.74 M
|
$1.89 M
|
$1.68 M
|
| Depreciation & Amortization |
$4.32 M
|
$3.79 M
|
$2.98 M
|
$2.11 M
|
$2.42 M
|
$2.77 M
|
$2.53 M
|
$2.29 M
|
$1.63 M
|
$881.00 K
|
| EBITDA |
-$249.78 M |
-$176.14 M |
-$66.42 M |
-$61.91 M |
$2.54 M |
-$146.10 M |
-$77.74 M |
-$55.95 M |
-$59.87 M |
-$42.14 M |
| EBITDA Ratio |
-4.82
|
-2.76
|
-1.14
|
-1.2
|
0.06
|
-8.39
|
-18.39
|
-28.12
|
-31.13
|
-22.33
|
| Operating Income Ratio |
-5.21
|
-2.7
|
-1.41
|
-1.53
|
-1.79
|
-3.61
|
-20.3
|
-29.71
|
-32.2
|
-22.96
|
| Total Other Income/Expenses Net |
$4.08 M
|
-$21.73 M
|
$1.65 M
|
$7.62 M
|
$71.48 M
|
-$92.79 M
|
-$570.00 K
|
-$860.00 K
|
-$1.46 M
|
-$1.38 M
|
| Income Before Tax |
-$265.94 M
|
-$193.51 M
|
-$80.74 M
|
-$71.04 M
|
-$6.55 M
|
-$155.64 M
|
-$86.37 M
|
-$59.98 M
|
-$63.39 M
|
-$44.70 M
|
| Income Before Tax Ratio |
-5.13
|
-3.04
|
-1.38
|
-1.38
|
-0.15
|
-8.94
|
-20.43
|
-30.14
|
-32.96
|
-23.69
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.29 M
|
$272.00 K
|
$0.00
|
| Net Income |
-$265.94 M
|
-$193.51 M
|
-$80.74 M
|
-$71.04 M
|
-$6.55 M
|
-$155.64 M
|
-$86.37 M
|
-$57.69 M
|
-$63.39 M
|
-$44.70 M
|
| Net Income Ratio |
-5.13
|
-3.04
|
-1.38
|
-1.38
|
-0.15
|
-8.94
|
-20.43
|
-28.99
|
-32.96
|
-23.69
|
| EPS |
-1.42 |
-1.22 |
-1.09 |
-1.04 |
-1.05 |
-2.56 |
-1.91 |
-1.57 |
-2.2 |
-1.8 |
| EPS Diluted |
-1.42 |
-1.22 |
-1.02 |
-0.97 |
-0.98 |
-2.56 |
-1.91 |
-1.57 |
-2.2 |
-1.8 |
| Weighted Average Shares Out |
$187.24 M
|
$158.27 M
|
$79.83 M
|
$76.88 M
|
$76.39 M
|
$60.75 M
|
$45.27 M
|
$38.12 M
|
$28.82 M
|
$24.82 M
|
| Weighted Average Shares Out Diluted |
$187.24 M
|
$158.27 M
|
$85.60 M
|
$82.64 M
|
$82.16 M
|
$60.75 M
|
$45.27 M
|
$38.12 M
|
$28.82 M
|
$24.82 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
